U.S. Patent Disclosures
Friday, January 18, 2013
Lithera Inc., of San Diego, was issued a notice of allowance for its U.S. patent application, related to LIPO-202 (Salmeterol Xinafoate for Injection). LIPO-202 is being developed for selective, nonablative, local fat reduction.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.